Chronic adult T-cell Leukemia in a young male after blood transfusion as a newborn

Magali Colucci, Camila Cánepa, Matías Ruggieri, Carolina Berini, Nora Halperin, Francisca Rojas, Alejandra Altube, Cecilia Cabral Lorenzo, Alberto Deves, Olivier Hermine, Mirna Biglione

Abstract


Human T-cell Lymphotropic virus type 1 (HTLV-1) is the etiological agent of Adult T-cell Leukemia/Lymphoma (ATLL) and HTLV-1 Associated Myelopathy/Tropical Spastic Paraparesis (HTM/TSP). Areas of extremely high HTLV-1 prevalence are surrounded by areas of middle or very low prevalence. ATLL is an aggressive lymphoproliferative malignancy of peripheral T cells, with an incidence of less than 5% in HTLV-1-infected individuals. ATLL developed in the majority of cases in individuals who were infected with HTLV-1 by their mothers due to prolonged breastfeeding. In non-endemic areas, ATLL is usually limited to immigrants, their sexual partners and descendants from endemic regions. Very few cases of ATLL have been diagnosed in recipient patients few years after an organ transplantation or blood transfusion worldwide. Achieving an accurate and fast diagnosis of ATLL can be challenging due to the lack of professional experience, delayed consultation and difficulty in its sub-classification. We present a case of a delayed onset of a chronic ATLL in an 18-years-old male who was transfused with blood components as a premature newborn in Buenos Aires, a non-endemic city of South America.


Keywords


ATLL, Chronic, HTLV-1, Blood transfusion, Latency

Full Text:

PDF

References


Gessain A, Cassar O. Epidemiological Aspects and World Distribution of HTLV-1 Infection. Front Microbiol. 2012; 3:388.

Hino S. Establishment of the milk-borne transmission as a key factor for the peculiar endemicity of human T-lymphotropic virus type 1 (HTLV-1): the ATL Prevention Program Nagasaki. Proc Jpn Acad Ser B Phys Biol Sci 2011; 87:152–66.

Glowacka I, Korn K, Potthoff SA, et al. Delayed Seroconversion and Rapid Onset of Lymphoproliferative Disease After Transmission of Human T-Cell Lymphotropic Virus Type 1 From a Multiorgan Donor. Clin infectious disease. 2013; 1417-24.

Pombo-de-Oliveira MS, Carvalho SM, Borducchi D, et al. Adult T-cell leukemia/lymphoma and cluster of HTLV-I associated diseases in Brazilian settings. Leuk Lymphoma. 2001; 42(1-2):135-44.

Sibon D, Cassar O, Duga I, et al. Adult T-Cell Leukemia/Lymphoma in a Caucasian Patient After Sexual Transmission of Human T-Cell Lymphotropic Virus Type 1. Open Forum Infect Dis. 2015; 6;2(2):ofv032.

Matutes E. Adult T-cell leukaemia/lymphoma. Journal of Clinical Pathology. 2007; 60(12):1373–77.

Shimoyama M. Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma. A report from the lymphoma study group (1984–87) British Journal of Haematology.1991; 79(3):428-37.

Atae Utsunomiya, Ilseung Choi, Dai Chihara et al. Recent advances in the treatment of adult T-cell leukemia-lymphomas. Review Article. Cancer Sci. 2015; 106: 344-51.

Ishitsuka K, Tamura K. Treatment of adult T-cell leukemia/lymphoma: past, present, and future. European Journal of Haematology. 2008; 80(3):185-96.

Bazarbachi A, Plumelle Y, Carlos Ramos J, et al. Meta-analysis on the use of zidovudine and interferon-alfa in adult T-cell leukemia/lymphoma showing improved survival in the leukemic subtypes. J Clin Oncol. 2010;28(27):4177-83.




DOI: http://dx.doi.org/10.14319/ijcto.42.8

Creative Commons License
This work is licensed under a Creative Commons Attribution 3.0 License.

------------------------------------------------------------

International Journal of Cancer Therapy and Oncology (ISSN 2330-4049)

© International Journal of Cancer Therapy and Oncology (IJCTO)

To make sure that you can receive messages from us, please add the 'ijcto.org' domain to your e-mail 'safe list'. If you do not receive e-mail in your 'inbox', check your 'bulk mail' or 'junk mail' folders.

------------------------------------------------------------

Number of visits since October, 2013
AmazingCounters.com